The new system includes novel Single-Cell Automated Identification (SCAI) technology for AI-powered rapid single-cell verification and documented monoclonality reporting
Oxford (UK), November 5, 2024: iotaSciences, the Oxford-based leader in single-cell biology handling
solutions, announced today the upcoming launch of its newly developed Single-Cell Cloning Platform
XT at the Cell 2024 event in London (UK) from November 6-8, 2024.
The Single-Cell Cloning Platform XT is a next-generation instrument based on the existing Single-Cell
Cloning Platform and iotaSciences’ proprietary fluid-shaping technology. This upgraded platform offers
enhanced automation, from single-cell isolation and culture within miniature cell chambers to the
automated transfer of verified monoclonal cultures into 96-well plates to increase overall throughput
and speed. It also makes use of the newly developed SCAI technology for integrated Single-Cell
Automated Identification and provides a documented monoclonality report.
The Cloning Platform XT builds on the successful use of the first-generation instrument by cell biology
& gene therapy researchers worldwide, with a particular focus on stem cell handling and gene editing.
Given its additional features, the new platform is now also suitable for cell line development and
reporter cell line generation work.
iotaSciences’ Chief Product Officer, Dr Alexander Feuerborn, said: “We are highly excited about the
availability of our new Single-Cell Cloning Platform XT, which addresses our customers’ need to receive
a full plate of verified monoclonal cultures with reliable, high-quality, results in a documented manner.
In addition, we are very proud to debut our newly developed SCAI technology in this next-generation
single-cell handling solution.”
“This product advancement is further proof of our strategy to position iotaSciences as a leader in the
rapidly evolving field of single-cell biology handling by bringing pioneering novel solutions to this
space”, Dr Michael Lutz, CEO at iotaSciences, commented. “Such solutions are key to R&D workflows
related to Cell and Gene Therapy (CGT) and other applications, and represent a multimillion-dollar
market potential in the coming years.”
About iotaSciences (https://iotasciences.com):
iotaSciences is a spin-out from the University of Oxford (UK), founded in 2016 by scientists from the Department of Engineering Science and the Sir William Dunn School of Pathology. Since its inception, iotaSciences has been committed to offer researchers highly user-friendly, reliable, and powerful single cell handling technologies and solutions with unique capabilities that greatly simplify and facilitate breakthrough advances in cell biology and gene therapy.
For further information please contact:
iotaSciences Ltd.
Dr Michael Lutz, Chief Executive Officer
Tel: +44 (1865) 309630
Email: info@iotasciences.com